Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III

被引:12
|
作者
Kern, David M. [1 ]
Balu, Sanjeev [2 ]
Tunceli, Ozgur [1 ]
Anzalone, Deborah [2 ]
机构
[1] HealthCore Inc, Wilmington, DE 19801 USA
[2] AstraZeneca Pharmaceut LP, Wilmington, DE USA
关键词
Adherence; Coronary heart disease; Dyslipidemia; Retrospective; Statins; MEDICATIONS; GUIDELINES; UPDATE;
D O I
10.1185/03007995.2014.971151
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To compare clinical characteristics, statin treatment patterns and adherence among patients at different risk for coronary heart disease (CHD) as defined by National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines. Methods: Patients >= 18 years old with >= 1 claim for dyslipidemia, >= 1 statin claim, or >= 1 LDL-C value >= 100 mg/dL were identified from 1 January 2007 to 31 July 2012. Patients were classified as low risk (LR) (0-1 risk factor: hypertension, age >= 45 years [men] or >= 55 years [women], or low HDL-C), moderate/moderately high risk (MR) (>= 2 risk factors), high risk (HR) (CHD or CHD risk equivalent), or very high risk (VHR) (acute coronary syndrome, or established cardiovascular disease plus diabetes or metabolic syndrome). Medication use and lipid levels during the 12 months before and statin use during the 6 months after index were compared across risk groups. Results: There were 1,524,351 LR, 242,357 MR, 188,222 HR, and 57,469 VHR patients identified. Statin use was observed in 15% of all patients, but was higher in the VHR group (45%) versus LR (12%), MR (18%), and HR (29%) groups. Simvastatin accounted for 50%-52% of all statin use, and average statin dose was higher among VHR patients compared with all other groups. Adherence was low overall (mean proportion of days covered [PDC]: 0.57), but higher among VHR (0.69) versus others (mean PDC: 0.55, 0.59, and 0.59 in LR, MR, and HR groups, respectively). Conclusions: Statin treatment was low across all risk groups, and VHR patients had higher doses and better adherence compared with other risk groups. However, adherence was not optimal, indicating a potential limited benefit from statin treatment.
引用
收藏
页码:2443 / 2451
页数:9
相关论文
共 50 条
  • [21] Evaluation of the National Cholesterol Education Panel algorithm Adult Treatment Panel III algorithm in the A to Z trial
    de Lemos, JA
    Wiviott, SD
    Murphy, SA
    Lewis, EF
    Palmisano, J
    Bilheimer, DW
    Pfeffer, MA
    CIRCULATION, 2005, 112 (17) : U544 - U544
  • [22] The usefulness of the International Diabetes Federation and the National Cholesterol Education Program's Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes
    Tong, Peter C.
    Kong, Alice P.
    So, Wing-Yee
    Yang, Xilin
    Ho, Chung-Shun
    Ma, Ronald C.
    Ozaki, Risa
    Chow, Chun-Chung
    Lam, Christopher W.
    Chan, Juliana C. N.
    Cockram, Clive S.
    DIABETES CARE, 2007, 30 (05) : 1206 - 1211
  • [23] Use of a handheld assist device for cholesterol management by national cholesterol education panel Adult Treatment Panel III guidelines
    Rashid, M
    Goebel, L
    Wehner, P
    Seifu, M
    Gress, T
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : S275 - S275
  • [24] Distribution of low-density lipoprotein cholesterol levels and treatment patterns in treatment-eligible United States Adults based on the National Cholesterol Education Program Adult Treatment Panel III guidelines
    Bell, TJ
    Hoerger, TJ
    Tran, MH
    Candrilli, SD
    Wojczynski, MK
    AMERICAN HEART JOURNAL, 2002, 144 (05) : 915 - 915
  • [25] Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III Report
    Grundy, SM
    AMERICAN JOURNAL OF CARDIOLOGY, 2005, 96 (01): : 47D - 50D
  • [26] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [27] Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, R
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Cleeman, JI
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    Keller, SA
    Jehle, AJ
    CIRCULATION, 2002, 106 (25) : 3143 - 3421